mj CBIS accumulation@ .03/licensing deal/8products launching this month
the news keeps coming from CBIS. Back to Back company press releases this week including Licensing deal.
CBIS Expands Licensing Deal with Purple Haze Properties as it Launches 'Jimi's Cannabis Collection' Today at the Chicago 'Marijuana Business Conference and Expo'PR Newswire(Tue 10:42AM EDT)Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform
(interesting on Purple Haze’ concept) ....Purple Haze Properties will be launching its concept of the Purple Haze Lounges worldwide and will be looking at Denver and Los Angeles for the first ground breaking locations and then Jamaica and Vancouver, B.C, as potential international future locations. These 20,000 sq. ft. "Ultra Lounges" will have a concert hall, restaurants, VIP memberships and charity foundation with themed social areas....The property will utilize the best music and video technologies and have some of the finest functional glass art ever seen....
The announcement above followed another company pr regarding a major product line from their sister company, which they hold a substantial stake in.
OmniCanna Health Solutions, Inc. (ENDO) Names Greta Gaines as CEO & President as Company Prepares for US Release of 'The Hempery' Product Line on May 20, 2015PR Newswire(Mon 9:18AM EDT)OmniCanna Health Solutions, Inc. (ENDO) (fka "Endocan Corporation"
, a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce that the Company's Board of Directors has selected Greta Gaines as its new CEO and President following her appointment to the Board. The Company takes this action concurrently with the impending release of the Company's new skin care product line: The Hempery TM. On May 20, 2015 ....
Just prior to the recent headlines we prepared a profile which expands on the fundamentals and technicals which have both become quite appealing...Read on...
Keeping a closer eye on MJ proxy CBIS with Recent Acquisition / Bullish Cohen report / Eight new product releases this month in Europe.
cannabis-science-logo
Focus on base building near .03 as they are set to monetize with extremely rapid revenue acceleration forecast in the next 4 years.
Earlier in May they announced a major acquisition in an interesting sector...What stands out from the pr is how quick plan to make it to market
Cannabis Science Acquires Pet Care Manufacturer and Distributor Equi-Pharm & Enters the $60 Billion Pet Care IndustryPR Newswire(Thu, May 7)......”We are currently developing the first three new cannabinoid-enriched pet products right now and will be available to the pet market within a matter of weeks through our current distribution channels.....”
Earlier this spring, Cohen Research issued an extensive and quite bullish report on CBIS with a .19 price target.
They referred to the stock as one of the few MJ related pure plays. The company was created back in 2009 before all the johnny come latelys hit the market on the sector.
What particularly stood out within report from The Cohen Report::
In a few short months, new CEO and President Mr. Raymond C. Dabney has restructured and redirected the business model, adding revenue producing businesses and expanding the CBIS footprint worldwide......Management has built strong partnerships....The Company estimates forecast revenues will grow from $0.1 million in FYE December 31, 2015 to approximately $64.52 million by FYE 2020.
This report really takes on an objective approach, and takes into account the risks, but overall, it accurately depicts on how all of their intellectual properties are about to pay off big time
For more, goto http://cohengrassroots.com/Reports/Cannabis_S...3_2015.pdf
On the research side, CBIS is taking a major lead in alternative/mj options for the treatment of HIV and other serious diseases for patients who have essentially run out of time.
Cannabis Science (CBIS) Featured in HIV Plus Magazine; National HIV Patient Magazine Brings Attention to CBIS Approach to Research on Treating HIV-Driven Inflammation with Cannabinoids
The article - published in the March/April 2015 issue of HIV Plus is highlighting Cannabis Science's clinical research programs to develop cannabinoid-based treatments for Kaposi's sarcoma and HIV-driven inflammation. Recent peer-reviewed publications have demonstrated the potential of cannabinoids to address these two diseases, for which new treatments are urgently needed. Cannabis Science is the only company working on the development of cannabinoid-based drugs for Kaposi's sarcoma and HIV-driven inflammation.
With regard to the seriousness of their research, they will be presenting at an upcoming conference. Worth noting, they are the list of the largest contributors and supporting organizations for the event.
9th Annual National Clinical Conference on Cannabis Therapeutics 2015Event Dates: May 21, 2015 - May 24, 2015
Event Website: http://patientsoutoftime.org/florida-2015/
Conference (more)
patientsoutoftime
On the technical side:
We are focusing on the long term chart. Notice the stock is back at the levels it was (near .03) prior to it’s metoric rise at the start of 2014.
Notice how the stock has begun to firm .03. We keep noticing constant signs of accumulation everytime the stock dips at or just below it.
Cannabis Science, Inc. (CBIS)
Bottom Line:
First of all, the stock is sitting at a 2 year low.....Second they are about to go commerical and not just with one product...News has been steadily increasing and so has their presence in several publications and conferences.......Projections are quite bullish and very realistic in our opinion.
What their new CEO has done in just a few short months/The number of alliances he has established is proof in clout/drive......In addition, potential investors can’t forget their ever expanding intellectual property which is the real key here.
Technically, accumulation signs are becoming increasingly evident near .03
One must factor other factors as well...If this country decides to go legal on the national level, which obviously seems to be where it’s trending.
With all said, the risk/reward at present levels is increasingly appealing.
source: Greenbackers
the news keeps coming from CBIS. Back to Back company press releases this week including Licensing deal.
CBIS Expands Licensing Deal with Purple Haze Properties as it Launches 'Jimi's Cannabis Collection' Today at the Chicago 'Marijuana Business Conference and Expo'PR Newswire(Tue 10:42AM EDT)Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform
(interesting on Purple Haze’ concept) ....Purple Haze Properties will be launching its concept of the Purple Haze Lounges worldwide and will be looking at Denver and Los Angeles for the first ground breaking locations and then Jamaica and Vancouver, B.C, as potential international future locations. These 20,000 sq. ft. "Ultra Lounges" will have a concert hall, restaurants, VIP memberships and charity foundation with themed social areas....The property will utilize the best music and video technologies and have some of the finest functional glass art ever seen....
The announcement above followed another company pr regarding a major product line from their sister company, which they hold a substantial stake in.
OmniCanna Health Solutions, Inc. (ENDO) Names Greta Gaines as CEO & President as Company Prepares for US Release of 'The Hempery' Product Line on May 20, 2015PR Newswire(Mon 9:18AM EDT)OmniCanna Health Solutions, Inc. (ENDO) (fka "Endocan Corporation"
, a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce that the Company's Board of Directors has selected Greta Gaines as its new CEO and President following her appointment to the Board. The Company takes this action concurrently with the impending release of the Company's new skin care product line: The Hempery TM. On May 20, 2015 .... Just prior to the recent headlines we prepared a profile which expands on the fundamentals and technicals which have both become quite appealing...Read on...
Keeping a closer eye on MJ proxy CBIS with Recent Acquisition / Bullish Cohen report / Eight new product releases this month in Europe.
cannabis-science-logo
Focus on base building near .03 as they are set to monetize with extremely rapid revenue acceleration forecast in the next 4 years.
Earlier in May they announced a major acquisition in an interesting sector...What stands out from the pr is how quick plan to make it to market
Cannabis Science Acquires Pet Care Manufacturer and Distributor Equi-Pharm & Enters the $60 Billion Pet Care IndustryPR Newswire(Thu, May 7)......”We are currently developing the first three new cannabinoid-enriched pet products right now and will be available to the pet market within a matter of weeks through our current distribution channels.....”
Earlier this spring, Cohen Research issued an extensive and quite bullish report on CBIS with a .19 price target.
They referred to the stock as one of the few MJ related pure plays. The company was created back in 2009 before all the johnny come latelys hit the market on the sector.
What particularly stood out within report from The Cohen Report::
In a few short months, new CEO and President Mr. Raymond C. Dabney has restructured and redirected the business model, adding revenue producing businesses and expanding the CBIS footprint worldwide......Management has built strong partnerships....The Company estimates forecast revenues will grow from $0.1 million in FYE December 31, 2015 to approximately $64.52 million by FYE 2020.
This report really takes on an objective approach, and takes into account the risks, but overall, it accurately depicts on how all of their intellectual properties are about to pay off big time
For more, goto http://cohengrassroots.com/Reports/Cannabis_S...3_2015.pdf
On the research side, CBIS is taking a major lead in alternative/mj options for the treatment of HIV and other serious diseases for patients who have essentially run out of time.
Cannabis Science (CBIS) Featured in HIV Plus Magazine; National HIV Patient Magazine Brings Attention to CBIS Approach to Research on Treating HIV-Driven Inflammation with Cannabinoids
The article - published in the March/April 2015 issue of HIV Plus is highlighting Cannabis Science's clinical research programs to develop cannabinoid-based treatments for Kaposi's sarcoma and HIV-driven inflammation. Recent peer-reviewed publications have demonstrated the potential of cannabinoids to address these two diseases, for which new treatments are urgently needed. Cannabis Science is the only company working on the development of cannabinoid-based drugs for Kaposi's sarcoma and HIV-driven inflammation.
With regard to the seriousness of their research, they will be presenting at an upcoming conference. Worth noting, they are the list of the largest contributors and supporting organizations for the event.
9th Annual National Clinical Conference on Cannabis Therapeutics 2015Event Dates: May 21, 2015 - May 24, 2015
Event Website: http://patientsoutoftime.org/florida-2015/
Conference (more)
patientsoutoftime
On the technical side:
We are focusing on the long term chart. Notice the stock is back at the levels it was (near .03) prior to it’s metoric rise at the start of 2014.
Notice how the stock has begun to firm .03. We keep noticing constant signs of accumulation everytime the stock dips at or just below it.
Cannabis Science, Inc. (CBIS)
Bottom Line:
First of all, the stock is sitting at a 2 year low.....Second they are about to go commerical and not just with one product...News has been steadily increasing and so has their presence in several publications and conferences.......Projections are quite bullish and very realistic in our opinion.
What their new CEO has done in just a few short months/The number of alliances he has established is proof in clout/drive......In addition, potential investors can’t forget their ever expanding intellectual property which is the real key here.
Technically, accumulation signs are becoming increasingly evident near .03
One must factor other factors as well...If this country decides to go legal on the national level, which obviously seems to be where it’s trending.
With all said, the risk/reward at present levels is increasingly appealing.
source: Greenbackers
